MicroRNAs (miRNAs) are small non-coding RNA molecules, which act as post-transcriptional regulators of gene expression and have been implicated in initiation, progression and treatment outcome of diverse cancers. Single nucleotide polymorphisms (SNPs), as the most common type of genetic variation, also exist in miRNA genes and can lead to alteration in miRNA expression resulting in diverse functional consequences. Emerging studies have evaluated the association of miRNA SNPs with cancer risk, but the results remain inconclusive. To assess the relationship between miRNA SNPs and cancer risk, we performed a meta-analysis of 18 studies involving 20 660 subjects for miR-146a rs2910164 polymorphism and 21 studies involving 26,018 subjects for miR-196a2 rs11614913 polymorphism. As for rs2910164, no significant association of cancer risk was found in the overall analysis. In subgroup analysis by cancer type, ethnicity, source of controls and sample size, significant association of cancer risk was mainly found in papillary thyroid carcinoma, primary liver cancer, cervical cancer, Caucasian population and small sample size studies. For rs11614913, significant results were found in all the tested genetic models and T allele or its carriers were associated with decreased cancer risk in overall analysis (T vs. C: OR = 0.888, 95% CI 0.84-0.938; TT+TC vs. CC: OR = 0.897, 95% CI 0.828-0.971). In stratified analysis by cancer type and ethnicity, significant association of cancer risk was observed in breast cancer, lung cancer, colorectal cancer and Asian population, but not in Caucasian population. During further stratified analysis by source of controls and sample size, results similar to those of overall analysis were found in all of the subgroups. Taken together, our results indicated that miR-196a2 rs11614913 T variant probably contribute to decreased susceptibility to cancer. However, limited evidence was found for association of miR-146a rs2910164 with cancer risk, and further well-designed studies with large sample size will be necessary to validate the effect of miR-146a rs2910164 on cancer susceptibility.
Introduction
MiRNAs are a class of small, single-stranded endogenous RNAs with approximately 22 nucleotides in length, which act as post-transcriptional regulators of gene expression. It was estimated that a single miRNA could target hundreds of mRNAs and nearly 30% protein-coding genes in the human genome can be regulated by miRNAs (1) . Emerging evidence indicates that miRNAs are involved in important biological processes related to apoptosis, proliferation, differentiation, angiogenesis and immune response, the deregulation of which is crucial to carcinogenesis (2) . However, the exact mechanisms underlying miRNA deregulation in cancer remain largely unknown, which may possibly involve transcriptional deregulations, epigenetic or genetic variation, DNA copy number abnormalities and biogenesis defects in the miRNA machinery (3) . Deregulated miRNAs, which function as tumor suppressors or oncogenes, are associated with initiation, progression and treatment outcome of diverse cancers (4) .
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation, which are associated with population diversity, disease susceptibility and individual response to medicine (5) . SNPs located in miRNA-related regions including primary and precursor miRNA sequences, seed sequence of miRNAs, miRNA processing genes and 3'-untranslated regions of target genes, which may function as regulatory SNPs to modify miRNA production as well as the target binding affinity and specificity (6) . The first evidence that miRNA-related SNPs could affect disease susceptibility was provided by Abelson et al. who found that a variation in the miR-189-binding site of SLITRK1 was associated with Tourette's syndrome (7) . It was estimated that around 10% of human precursor miRNAs have documented SNPs, less than 1% of miRNAs have SNPs in the functional seed region and 2.4% of the target genes are polymorphic in 3'-untranslated regions (8) . Since a specific miRNA has the potential to regulate the expression of hundreds of target mRNAs, SNPs in miRNAs may produce more significant functional consequences and represent an ideal candidate for disease prediction.
The first study that investigated the effect of genetic variation in miRNA genes on cancer susceptibility was conducted by Calin et al. (9) , in which a germline mutation in pri-miR-16-1 was associated with low expression of miR-16-1 in familial chronic lymphocytic leukemia. Sine then, a number of studies were carried out to investigate the impact of miRNA SNPs on pathogenesis and susceptibility of malignant tumors. MiR-146a rs2910164 and miR-196a2 rs11614913 were the two most common studied miRNA polymorphisms (10) (11) (12) (13) (14) .
MiR-146a rs2910164 polymorphism is located at position +60 relative to the first nucleotide of pre-miR-146a with a G to C change in the passenger strand, which results in a change from G:U pair to C:U mismatch in the stem structure of miR-146a precursor and a reduced production of mature miR-146a (11). Jazdzewski et al. (15) found that the MiR-146a rs2910164 CC genotype in pre-miR-146a was associated with decreased mature miR-146a expression and increased influenced report genes, including genes involved in the Toll-like receptor and cytokine signaling pathway.
MiR-196a2 is composed of two different mature miRNAs (miR-196a-5P and miR-196a-3P) which are processed from the same stem-loop (16) . The expression of 137 cancer-related transcripts could be significantly altered after introduction of pre-miR-196a. Rs11614913 locates in the mature sequence of miR-196a-3P and could lead to less efficient processing of the miRNA precursor to its mature form, as well as diminished capacity to regulate target genes. Hoffman et al. (17) found that miR-196a2 rs11614913 not only influences the production level of mature miR-196a, but also has a phenotypic effect on target gene expression, as a total of 684 transcripts altered expression following introduction of pre-miR-196a-C, and fewer than half that number were significantly altered after introduction of pre-miR-196a-T.
In light of the biological effects of the two miRNA SNPs, emerging case-control studies have been done to evaluate the association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk in diverse populations. The tumor types included breast cancer (18) , liver cancer (19, 20) , lung cancer (21), colorectal cancer (22) , gastric cancer (23) and others (24) . However, the results of different studies remained inconclusive, because of limited sample size and heterogeneity. For example, Xu et al. (19) reported that the miR-146a rs2910164 polymorphism was associated with a significantly increased risk of hepatocellular carcinoma under a dominant model in a Chinese population, while Akkiz et al. (11) failed to find any association between the polymorphism with hepatocellular cancer under the same model in a Turkish population. As for miR-196a2 rs11614913, Tian et al. (21) found that homozygote CC was associated with significantly increased risk of lung cancer compared with the wild-type homozygote TT and heterozygote TC; while in a study of glioma, homozygote CC was associated with significantly decreased risk compared with T allele carriers (25) . And there are also studies reporting that the miR-196a2 rs11614913 polymorphism was not associated with cancer risk (13, 26) .
In addition, allele frequencies of two polymorphisms were different between ethnic groups, suggesting that the association between miRNA polymorphisms and cancer risk in the different populations may vary. According to dbSNPs database, the ancestral/derived alleles of the miRNA polymorphisms are G/C for miR-146a rs2910164 and C/T for miR-196a2 rs11614913, respectively. In a study of Caucasian population, the minor allele frequencies (MAF) were 0.231 (C allele) for miR-146a rs2910164 and 0.377 (T allele) for miR-196a2 rs11614913 (26) , while in an Asian population, the frequency of derived C allele for rs2910164 was 0.583 and the frequency of derived T allele for rs2910164 was 0.564 (27) .
In order to better assess the association of these SNPs in miRNAs with cancer risk, we conducted a meta-analysis on all eligible case-control studies to clarify the effect of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms on overall cancer risk. The effects of tumor site, ethnicity, source of controls and sample size were also evaluated.
Material and methods

Identification and eligibility of relevant studies
To identify all articles that explored the association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk, we conducted a literature search of Embase and Medline database (up to December 2011) using the following search terms: 'microRNA' and 'cancer' and 'polymorphism' as well as their combinations, without any restriction on language. All eligible studies were retrieved, and their references were checked for other relevant publications. Review articles and bibliographies of other relevant studies identified were hand searched to find additional eligible studies.
Inclusion criteria
Studies included in the meta-analysis had to meet all the following criteria: (i) use an unrelated case-control design, (ii) genotype distribution of control population must be in Hardy-Weinberg equilibrium (HWE) and (iii) sufficient published data for calculating odds ratios (ORs) with their 95% confidence intervals (95% CIs).
Data extraction
For all of the eligible publications, the following data was extracted independently by two investigators (Liu and Zhang): first author's surname, year of publication, country origin, cancer type, characteristics of controls and matching criteria, study design, ethnicity, genotyping methods, total number of cases and controls, and allele frequencies of cases and controls for miR-146a G/C and miR-196a2 T/C genotypes, respectively. (Supplementary Tables S1 and S2 , available at Mutagenesis Online) Disagreements were resolved by discussion between the two review authors. Different ethnicity descents were categorised as Caucasian, Asian and mixed population.
Statistical analysis
The deviation of allele frequencies in controls from HWE were calculated using the goodness-of-fit test and a P-value less than 0.05 was considered significant. Crude ORs with 95% CIs were used to assess the strength of association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk. Heterogeneity assumption was checked by the chi-square-based Q-test, and a P-value greater than 0.1 indicates a lack of heterogeneity among studies, so the pooled OR estimate of each study was calculated by the fixed-effects model (the Mantel-Haenszel method). Otherwise, the random-effects model (the DerSimonian and Laird method) was used (28) . The significance of the pooled OR was determined by the Z-test, and P < 0.05 was considered statistically significant. The pooled ORs were calculated by allele, heterozygote, homozygote, dominant model and recessive model comparisons (18) . For each genetic comparison, subgroup analysis was considered by ethnicity and cancer types. Publication bias was assessed with funnel plots and Egger's tests. An asymmetric plot and p value greater than 0.10 for Egger's tests suggest a possible publication bias (29) . All statistical analyses were carried out with STATA software, version 10.0 (STATA Corp., College Station, TX, USA) and all P values were two-sided.
Results
Selection of studies
Forty-eight studies were identified for further evaluation achieved by search of the Embase and Medline with different combination of key terms ( Figure 1 ). Another study was identified through hand search of references (30) . During the extraction of data, 17 studies were excluded, because they were not case-control studies (18, 22, (31) (32) (33) (34) (35) (36) (37) (38) and did not provide detailed allele frequencies needed for OR calculation (39) (40) (41) (42) (43) , or significantly deviated from HWE (44, 45) . Parts of data in Catucci's and Zhang's studies concerning the miR146a rs2910164 polymorphism were also excluded because of significant departure from HWE (26, 46) . In two studies, genotype frequencies were presented separately according to country of study subjects, and thus each of these studies was considered separately for meta-analysis (15, 26) .
A total of 18 studies involving 9207 cases and 11 453 controls were ultimately analysed for miR-146a rs2910164 (10) (11) (12) (13) 15, 19, 21, 24, 26, 27, (47) (48) (49) (50) (51) (52) (53) (54) ) and 21 studies involving 11 764 cases and 14 254 controls for miR-196a2 rs11614913 (11-13,17,21,23-27, 30,46,48,55-62) . As for rs2910164, there were three primary liver cancer, three papillary thyroid carcinoma (PTC), three gastric cancer, two breast cancer, two cervical cancer and seven other types of cancer studies. The ethnicity background of 12 studies was Asian and that of six studies was Caucasian. For miR-196a2 rs11614913 polymorphism, there were four breast cancer, four liver cancer, three lung cancer, three colorectal cancer, two gastric cancer and five other types of cancer studies. The ethnicity backgrounds of 16 studies, 4 studies and 1 study were Asian, Caucasian and mixed population, respectively. The controls of all studies mainly came from cancer-free population and were matched for sex and age. Multiple genotyping methods had been employed in the studies including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), polymerase chain reaction-ligation detection reaction (PCR-LDR), Taqman SNP genotyping, MassARRAY multiplex and others.
Quantitative analysis
All genotypes and allele frequencies of cases and controls are shown in Supplementary Tables S1 and S2, available at Mutagenesis Online. For miR-146a rs2910164 polymorphism, the minor allele of Caucasians was derived C allele, and MAF in cases and controls of Caucasians were 0.249 and 0.231, respectively. In Asians, the frequencies of derived C allele in cases and controls were 0.509 and 0.546, respectively. The genotype CC of cases and controls in Caucasians (5.8% and 5.5%, respectively) were less prevalent than those in Asians (26.9% and 30.3%, respectively). For miR-196a2 rs11614913 polymorphism, the minor allele of Caucasians was derived T allele, and the MAF in cases and controls of Caucasians were 0.385 and 0.386, respectively. In Asians, the frequencies of derived T allele in cases and controls were 0.501 and 0.535, respectively. The genotype TT of cases and controls in Caucasians (0.148 and 0.154 respectively) was less prevalent than those in Asians (0.254 and 0.29, respectively).
When 18 studies on miR-146a rs2910164 polymorphism were pooled into the meta-analysis, no significant association of cancer risk was found in all the five genetic models. In the stratified analysis by cancer type, homozygote GG had an effect of increasing the risk of liver cancer compared with homozygote CC (P = 0.025, GG vs. CC: OR = 1.396, 95% CI = 1.043-1.87, P heterogeneity = 0.308). In the study of PTC, the GC heterozygous state associated with increased risk of acquiring PTC (P < 0.001, GG vs. GC: OR = 0.675, 95% CI =0.543-0.84, P heterogeneity = 0.323). And both homozygous states were protective: OR = 0.753 for GG vs. GC+CC (95% CI 0.609-0.931) and OR = 2.675 for GG+GC vs. CC (95% CI 1.482-4.828). For cervical cancer, G allele or its carriers showed a significant increased cancer susceptibility in all genetic models tested. Furthermore, there were not significantly increased risks Figure 2) .
In the subgroup analysis by ethnicity, homozygote GG was associated with decreased cancer risk compared with heterozygote GC and C allele carriers (GG vs. GC: P = 0.008, OR = 0.876, 95% CI = 0.795-0.966, P heterogeneity = 0.179; GG vs. GC+CC: P = 0.008, OR = 0.88, 95% CI = 0.802-0.967, P heterogeneity = 0.545) and G allele also had an effect of decreasing cancer risk among Caucasians (G vs. C: P = 0.022, OR = 0.915, 95% CI = 0.847-0.987 P heterogeneity = 0.71). In Asians, no significant cancer risk was found in all the tested genetic models (Table I and Figure 3) .
In stratified analysis by source of controls, no significant effects were observed in both population-based and hospital studies in all the tested genetic models. The data were also stratified, on the basis of sample size, into two subgroups: small sample (the total number of controls and cases less than 1000) and large sample (the total number of controls and cases not less than 1000) subgroups. Among small sample size subgroups, homozygote CC associated with decreased cancer risk compared with homozygote GG and G allele carriers (GG vs. CC: P < 0.001, OR = 1.686, 95% CI = 1.437-1.979, P heterogeneity = 0.113; GG+GC vs. CC: P = 0.001, OR = 1.405, 95% CI = 1.156-1.708, P heterogeneity = 0.029) and C allele also had an effect of decreasing cancer risk (G vs. C: P = 0.039, OR = 1.127, 95% CI = 1.006-1.263, P heterogeneity = 0.002). In the large sample size subgroup, a statistically significant result was found in allele comparison (G vs. C: P = 0.009, OR = 0.931, 95% CI = 0.882-0.983, P heterogeneity = 0.257) ( Table I) .
For miR-196a2 rs11614913 polymorphism, significant association of cancer risk was found in all the five genetic models after analysis of 21 studies. In the stratified analysis by cancer type, significant cancer risk was found in the all the five genetic models among breast cancer and colorectal cancer. For lung cancer, carriage of the T variant was also found to be associated with decreased cancer risk (Table I and Figure 4) .
In the subgroup analysis by ethnicity, a significant association between rs11614913 and cancer risk was found in all the genetic models among Asians. But for Caucasian, five kinds of genetic models did not produce a statistically significant association of cancer risk (Table I and Figure 5 ).
In stratified analysis by source of controls, homozygote TT was associated with decreased cancer risk compared with homozygote CC and C allele carriers (TT vs. CC: P = 0.005, OR = 0.84, 95% CI = 0.744-0.949, P heterogeneity = 0.638; TT vs. TC+CC: P = 0.027, OR = 0.891, 95% CI = 0.804-0.987, P heterogeneity = 0.873) and T allele also had an effect of decreasing cancer risk compared with C allele (T vs. C: P = 0.012, OR = 0.927, 95% CI = 0.875-0.983, P heterogeneity = 0.293) among population-based studies. In hospital-based studies, the rs11614913 was associated with cancer risk in all genetic models. When stratified on the basis of sample size, significant association of cancer risk was found in all the tested genetic models among small sample subgroups. In large sample size subgroups, statistically significant results were found in all tested genetic models but for the recessive model comparison. (TT+TC vs. CC: P = 0.119, OR = 0.927, 95% CI = 0.843-1.02, P heterogeneity = 0.038) ( Table I) .
Publication bias
Begg's funnel plot and Egger's test were performed to access the publication bias of literatures, and no evidence of publication bias was observed. Then, the Egger's test was used to provide statistical evidence of funnel plot symmetry in recessive model (P = 0.254 for rs2910164; P = 0.356 for rs11614913). Finally, a single study involved in the meta-analysis was deleted each time to reflect the influence of the individual dataset to the pooled ORs. The corresponding pooled ORs were not materially altered for both polymorphisms.
Discussion
SNPs are the most common genetic sequence variation in human genome affecting sequences' coding and splicing, which can influence the cancer susceptibility in population (63) . MiRNAs are a class of small, single-stranded noncoding RNAs involved in important biological processes related to apoptosis, proliferation, differentiation, angiogenesis and immune response (2) . SNPs in miRNAs can affect miRNA function by modulating the transcription of the primary transcript, pri-miRNA and pre-miRNA processing and maturation, or miRNA-mRNA interactions, which could possibly contribute to cancer susceptibility (64) . Recently, a number of studies have investigated the role of miRNA SNPs in cancer susceptibility, but the results remain inconclusive. The present meta-analysis focused on the association of two most common studied miRNA polymorphisms (miR-146a rs2910164 and miR-196a2 rs11614913) with cancer risk, which included a total of 18 studies involving 9207 cases and 11 453 controls for rs2910164 and 21 studies involving 11 764 cases and 14 254 controls for rs11614913. For miR-146a rs2910164, no significant association of cancer risk was found in overall analysis. In subgroup analysis by cancer type, significant association of cancer risk was only observed in primary liver cancer, papillary thyroid carcinoma and cervical cancer. Homozygote CC genotype was associated with a decreased cancer risk compared with genotype GG in papillary thyroid carcinoma, primary liver cancer and cervical cancer. In subgroup analysis by ethnicity, association of cancer risk in Caucasian was found in heterozygote, dominant model and allele comparisons, suggesting a possible role of genetic and environmental differences among different ethnicities. Hospital-based studies usually include controls with certain benign diseases, which are prone to develop malignancy and may not be very representative of the general population. When stratified by source of controls, no evidence of association between miR-146a rs2910164 and cancer risk was found in both population and hospital-based studies.
The publication bias is more serious in small sample size studies, as a small study that obtains a negative effect is not as likely to be published as large sample studies (65) . Thus, we analysed the data according to sample size. In studies with small sample size, allele G was associated with elevated cancer risk compared with allele C, and homozygote CC was associated with decreased cancer risk compared with GG and G allele carriers. However, in studies with large sample size, allele G was associated with decreased cancer risk in allele comparison, and no significant association of cancer risk was found in other genetic models. The results from large sample size studies were more reliable due to smaller publication bias, which is consistent to those of overall analysis.
Rs2910164 polymorphism is located in the 3p strand of miR-146a and involves a mispairing in the hairpin of the precursor, which leads to altered processing and lower expression of the mature sequence (35). Jazdzewski et al. (15) showed that the C allele of G/C polymorphism within the pre-miR-146a sequence reduced the production of mature miR-146a compared with the G allele. The C allele also interfered with the binding of a nuclear factor to pre-miR-146a. The reduction in miR-146a led to less-efficient inhibition of target genes involved in the Toll-like receptor and cytokine signaling pathway (TRAF6, IRAK1), deregulation of which is possibly involved in the carcinogenesis.
Despite the possible existence of the biological consequence of miR-146a rs2910164, the results of our meta-analysis did not support this due to absence of statistically significance in overall analysis and limited statistically significance in subgroup analysis. Further studies with larger sample size and deeper insights of biological mechanism are needed to elucidate the exact role of this polymorphism in cancer susceptibility. For rs11614913 polymorphism, we found that T allele or its carriers were associated with increased cancer risk. In subgroup analysis by cancer type, significant association of cancer risk was observed in breast cancer, lung cancer and colorectal cancer. And the results of comparison in different models were consistent among different cancer types. In subgroup analysis by ethnicity, association of cancer risk was mainly found in Asian population, suggesting a difference in genetic backgrounds between Asians and Caucasians. When further stratified by source of controls and sample size, significant association of cancer risk was found in nearly all the tested genetic models, which was consistent with the results of overall analysis.
Rs11614913 is located in the 3' passenger strand mature sequence of miR-196a. Biochemical studies on rs11614913 confirmed the results of our meta-analysis. Hoffman et al. (17) found that miR-196a rs11614913 polymorphism could influence endogenous processing of the miRNA precursor to its mature form and have an impact on target gene expression. Several cancer-related genes were altered following introduction of the pre-miR-196a-T vector compared with the pre-miR-196a-C vector. Deregulated HOX gene expression has been found in cancer including lung, prostate, breast, bladder, etc. (66) (67) (68) (69) . Members of HOX family including HOXB2, HOXB3, HOXC13 and HOXB5 were significantly downregulated in cells treated with pre-miR-196a-C. Two tumor suppressors (GADD45G and INHBB) were downregulated and several oncogenes (TP63 and genes encoding two calcium binding proteins) were upregulated in breast cancer cells after pre-miR-196a-C introduction, suggesting an oncogenic activity of pre-miR-196a-C and a protective role for pre-miR-196a-T (17, 70) .
The allele frequencies represent the incidence of gene variants and are a reflection of genetic diversity in a population (71) . In the meta-analysis, we found that the allele frequencies of miR-146a rs2910164 and miR-196a rs11614913 polymorphisms varied between different ethnic groups. For miR-146a rs2910164 polymorphism, the minor allele of Caucasians was derived C allele and MAF in cases and controls of Caucasians were 0.249 and 0.231, respectively. In Asians, the frequencies of derived C allele in cases and controls were 0.509 and 0.546, respectively. For miR-196a2 rs11614913 polymorphism, the minor allele of Caucasians was derived T allele and the MAF in cases and controls of Caucasians were 0.385 and 0.386, respectively. In Asians, the frequencies of derived T allele in cases and controls were 0.501 and 0.535, respectively. However, the MAF from dbSNPs database were 0.381 (C allele) for miR-146a rs2910164 and 0.388 (T allele) for miR-196a rs11614913, which were different from our results and came from a mixed global population. The difference in allele frequencies among races may partly explain the inconsistent results from subgroup analysis by ethnicity.
Although we performed the analysis with strict criteria for study inclusion and precise data extraction, significant between-study heterogeneity existed in all comparisons. After subgroup analysis stratified by tumor site, racial descent, source of controls and sample size, it can be found that the heterogeneity of the subgroups reduced significantly. Therefore, it can be presumed that the heterogeneity partly results from differences in ethnicity, tumor type, source of controls and sample size. Simultaneously, the heterogeneity may also be caused by the differences in the selection of subjects. Publication bias may exist because only published studies were included in this meta-analysis, although the result for publication bias was not statistically significant.
In conclusion, this meta-analysis provided evidence that miR-196a2 rs11614913 polymorphism is associated with an increased cancer risk and rs2910164 in miR-146a might be associated with susceptibility to papillary thyroid carcinoma and cervical cancer. However, it is necessary to conduct studies with homogeneous cancer patients and well-matched controls. Further studies estimating the effect of gene-gene and gene-environment interactions may eventually provide a better, comprehensive understanding of the role of miRNA polymorphisms in the initiation of cancer.
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